PBCAR-269A

N/A

Report date: 2023/09/22 20:07:23

Base Information

Drug NamePBCAR-269A

Drug Alias NamePBCAR-269A

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-cell maturation protein modulators

TargetsB-cell maturation protein

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPrecision Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPrecision Biosciences Inc

Active IndicationsN/A

Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A